Microneedle (MN) is the latest generation of transdermal drug delivery system composed of micron-sized needles for the delivery of a wide range of biopharmaceuticals. In the recent era, MN provides a great exibility toward the development of non-invasive insulin therapy by enhancing the transport of drug across the barrier stratum corneum. MN-mediated insulin delivery is not only overcome the limitations of conventional injections also provide steady-state plasma concentration for diabetes therapy. is editorial discusses the possibility of insulin-loaded MN product for the future diabetes therapy in relation to their patient acceptability.
Key words: Diabetes, insulin, microneedle